Drug intelligence / Profile preview

rClone30-IL24

Development stage
Preclinical
Modality
Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
Administration
Intratumoral
01

Overview

rClone30-IL24 is a recombinant Newcastle disease virus (NDV) engineered to express human interleukin-24 (IL-24). NDV is a member of the paramyxovirus family used as an oncolytic virus, naturally selective for tumor cells due to defects in their antiviral responses. By delivering IL-24—a tumor-suppressive cytokine with selective pro-apoptotic effects on cancer cells—directly into tumors, this construct aims to enhance antitumor immune responses and induce cancer cell death through multiple mechanisms, including activation of the JAK-STAT signaling pathway, increased reactive oxygen species (ROS) production, and upregulation of tumor suppressor proteins such as p53 and p21. This platform is under preclinical or early clinical investigation for solid tumors, with initial studies focusing on hepatocellular carcinoma and other malignancies.

02

Targets

IL-22R1/IL-20R2 (Interleukin-22 receptor subunit alpha-1/Interleukin-20 receptor subunit beta heterodimer)SIGMAR1 (Sigma non-opioid intracellular receptor 1)IL20RA/IL20RB (Interleukin-20 Receptor)STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on rClone30-IL24.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rClone30-IL24.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call